Author

Danielle Rud

Institution: Mayo Clinic

Observed institution: Mayo Clinic

OpenAlex ID: A5093396796

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations

2025 · Mithun Vinod Shah, Kevin Hung, et al. · Blood Advances · 22

Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations

2025 · Anmol Baranwal, Kimberly J. Langer, et al. · Blood Advances · 15

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort

2025 · Mithun Vinod Shah, Kevin Hung, et al. · Blood Cancer Journal · 13

Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms

2024 · Mithun V Shah, Kevin Hung, et al. · Blood · 1

Integrated prognostic model for TP53‑mutated myeloid neoplasms across all myeloid neoplasm subtypes

2025 · Devendra Hiwase, Steven Tessier, et al. · Blood

Interim Results of the CMML intercept study: A prospective observational study to evaluate the role of acute inflammation in CMML disease progression

2025 · Zhuoer Xie, Christy James, et al. · Blood

Single-Hit TP53mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

2023 · Devendra Hiwase, Anmol Baranwal, et al. · Blood

Works count: 7

Citation count: 51

H-index: 3

I10-index: 3